# Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

> **NCT01276236** · PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 13 (actual)

## Conditions studied

- Kaposi's Sarcoma

## Interventions

- **DRUG:** Maraviroc

## Key facts

- **NCT ID:** NCT01276236
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-09
- **Primary completion:** 2015-01-31
- **Final completion:** 2015-04-30
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2021-03-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01276236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01276236, "Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01276236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*